Replicative Adenovirus Vector (RGDCRAdCOX2F)

Phase 1Biologic

MMasonic Cancer Center, University of Minnesota

Replicative Adenovirus Vector (RGDCRAdCOX2F) is one of 3 biologic programs targeting Adenovirus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenovirusRecruiting

AdenovirusPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Adenovirus

#DrugCompanyPhaseTrials

Adenovirus Specific T- Lymphocytes

JJessie L. Alexander

Phase 2

1 2

Cytomegalovirus Specific T-Lymphocytes

JJessie L. Alexander

Phase 2

1 3

Replicative Adenovirus Vector (RGDCRAdCOX2F)

MMasonic Cancer Center, University of Minnesota

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Adenovirus

NCT06693986

Clinical

Trials by Indication[1]

Adenovirus1 trial

Adenovirus (RGDCRAdCOX2F)

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT06693986·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Replicative Adenovirus Vector (RGDCRAdCOX2F). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Replicative Adenovirus Vector (RGDCRAdCOX2F) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Replicative Adenovirus Vector (RGDCRAdCOX2F). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMasonic Cancer Center, University of Minnesota

Replicative Adenovirus Vector (RGDCRAdCOX2F)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Adenovirus1 trial

References

Drug Info

Quick Facts

Related News